A citation-based method for searching scientific literature

Josep M Llovet, Sergio Ricci, Vincenzo Mazzaferro, Philip Hilgard, Edward Gane, Jean-Frédéric Blanc, Andre Cosme de Oliveira, Armando Santoro, Jean-Luc Raoul, Alejandro Forner, Myron Schwartz, Camillo Porta, Stefan Zeuzem, Luigi Bolondi, Tim F Greten, Peter R Galle, Jean-François Seitz, Ivan Borbath, Dieter Häussinger, Tom Giannaris, Minghua Shan, Marius Moscovici, Dimitris Voliotis, Jordi Bruix. N Engl J Med 2008
Times Cited: 8233







List of co-cited articles
438 articles co-cited >1



Times Cited
  Times     Co-cited
Similarity


Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial.
Ann-Lii Cheng, Yoon-Koo Kang, Zhendong Chen, Chao-Jung Tsao, Shukui Qin, Jun Suk Kim, Rongcheng Luo, Jifeng Feng, Shenglong Ye, Tsai-Sheng Yang,[...]. Lancet Oncol 2009
47

Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial.
Masatoshi Kudo, Richard S Finn, Shukui Qin, Kwang-Hyub Han, Kenji Ikeda, Fabio Piscaglia, Ari Baron, Joong-Won Park, Guohong Han, Jacek Jassem,[...]. Lancet 2018
42

Regorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment (RESORCE): a randomised, double-blind, placebo-controlled, phase 3 trial.
Jordi Bruix, Shukui Qin, Philippe Merle, Alessandro Granito, Yi-Hsiang Huang, György Bodoky, Marc Pracht, Osamu Yokosuka, Olivier Rosmorduc, Valeriy Breder,[...]. Lancet 2017
35

Atezolizumab plus Bevacizumab in Unresectable Hepatocellular Carcinoma.
Richard S Finn, Shukui Qin, Masafumi Ikeda, Peter R Galle, Michel Ducreux, Tae-You Kim, Masatoshi Kudo, Valeriy Breder, Philippe Merle, Ahmed O Kaseb,[...]. N Engl J Med 2020
33

Nivolumab in patients with advanced hepatocellular carcinoma (CheckMate 040): an open-label, non-comparative, phase 1/2 dose escalation and expansion trial.
Anthony B El-Khoueiry, Bruno Sangro, Thomas Yau, Todd S Crocenzi, Masatoshi Kudo, Chiun Hsu, Tae-You Kim, Su-Pin Choo, Jörg Trojan, Theodore H Welling,[...]. Lancet 2017
32

Cabozantinib in Patients with Advanced and Progressing Hepatocellular Carcinoma.
Ghassan K Abou-Alfa, Tim Meyer, Ann-Lii Cheng, Anthony B El-Khoueiry, Lorenza Rimassa, Baek-Yeol Ryoo, Irfan Cicin, Philippe Merle, YenHsun Chen, Joong-Won Park,[...]. N Engl J Med 2018
830
32


Ramucirumab after sorafenib in patients with advanced hepatocellular carcinoma and increased α-fetoprotein concentrations (REACH-2): a randomised, double-blind, placebo-controlled, phase 3 trial.
Andrew X Zhu, Yoon-Koo Kang, Chia-Jui Yen, Richard S Finn, Peter R Galle, Josep M Llovet, Eric Assenat, Giovanni Brandi, Marc Pracht, Ho Yeong Lim,[...]. Lancet Oncol 2019
578
22

Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries.
Freddie Bray, Jacques Ferlay, Isabelle Soerjomataram, Rebecca L Siegel, Lindsey A Torre, Ahmedin Jemal. CA Cancer J Clin 2018
22

Pembrolizumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib (KEYNOTE-224): a non-randomised, open-label phase 2 trial.
Andrew X Zhu, Richard S Finn, Julien Edeline, Stephane Cattan, Sadahisa Ogasawara, Daniel Palmer, Chris Verslype, Vittorina Zagonel, Laetitia Fartoux, Arndt Vogel,[...]. Lancet Oncol 2018
927
18

Pembrolizumab As Second-Line Therapy in Patients With Advanced Hepatocellular Carcinoma in KEYNOTE-240: A Randomized, Double-Blind, Phase III Trial.
Richard S Finn, Baek-Yeol Ryoo, Philippe Merle, Masatoshi Kudo, Mohamed Bouattour, Ho Yeong Lim, Valeriy Breder, Julien Edeline, Yee Chao, Sadahisa Ogasawara,[...]. J Clin Oncol 2020
440
17

Modified RECIST (mRECIST) assessment for hepatocellular carcinoma.
Riccardo Lencioni, Josep M Llovet. Semin Liver Dis 2010
15

Diagnosis, Staging, and Management of Hepatocellular Carcinoma: 2018 Practice Guidance by the American Association for the Study of Liver Diseases.
Jorge A Marrero, Laura M Kulik, Claude B Sirlin, Andrew X Zhu, Richard S Finn, Michael M Abecassis, Lewis R Roberts, Julie K Heimbach. Hepatology 2018
14

Hepatocellular carcinoma.
Alejandro Forner, María Reig, Jordi Bruix. Lancet 2018
14

AASLD guidelines for the treatment of hepatocellular carcinoma.
Julie K Heimbach, Laura M Kulik, Richard S Finn, Claude B Sirlin, Michael M Abecassis, Lewis R Roberts, Andrew X Zhu, M Hassan Murad, Jorge A Marrero. Hepatology 2018
12

Hepatocellular Carcinoma.
Augusto Villanueva. N Engl J Med 2019
11

Prognostic factors and predictors of sorafenib benefit in patients with hepatocellular carcinoma: Analysis of two phase III studies.
Jordi Bruix, Ann-Lii Cheng, Gerold Meinhardt, Keiko Nakajima, Yoriko De Sanctis, Josep Llovet. J Hepatol 2017
272
11

New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1).
E A Eisenhauer, P Therasse, J Bogaerts, L H Schwartz, D Sargent, R Ford, J Dancey, S Arbuck, S Gwyther, M Mooney,[...]. Eur J Cancer 2009
10

Efficacy and Safety of Nivolumab Plus Ipilimumab in Patients With Advanced Hepatocellular Carcinoma Previously Treated With Sorafenib: The CheckMate 040 Randomized Clinical Trial.
Thomas Yau, Yoon-Koo Kang, Tae-You Kim, Anthony B El-Khoueiry, Armando Santoro, Bruno Sangro, Ignacio Melero, Masatoshi Kudo, Ming-Mo Hou, Ana Matilla,[...]. JAMA Oncol 2020
175
9

Ramucirumab versus placebo as second-line treatment in patients with advanced hepatocellular carcinoma following first-line therapy with sorafenib (REACH): a randomised, double-blind, multicentre, phase 3 trial.
Andrew X Zhu, Joon Oh Park, Baek-Yeol Ryoo, Chia-Jui Yen, Ronnie Poon, Davide Pastorelli, Jean-Frederic Blanc, Hyun Cheol Chung, Ari D Baron, Tulio Eduardo Flesch Pfiffer,[...]. Lancet Oncol 2015
465
9


SIRveNIB: Selective Internal Radiation Therapy Versus Sorafenib in Asia-Pacific Patients With Hepatocellular Carcinoma.
Pierce K H Chow, Mihir Gandhi, Say-Beng Tan, Maung Win Khin, Ariunaa Khasbazar, Janus Ong, Su Pin Choo, Peng Chung Cheow, Chanisa Chotipanich, Kieron Lim,[...]. J Clin Oncol 2018
254
8

Efficacy and safety of selective internal radiotherapy with yttrium-90 resin microspheres compared with sorafenib in locally advanced and inoperable hepatocellular carcinoma (SARAH): an open-label randomised controlled phase 3 trial.
Valérie Vilgrain, Helena Pereira, Eric Assenat, Boris Guiu, Alina Diana Ilonca, Georges-Philippe Pageaux, Annie Sibert, Mohamed Bouattour, Rachida Lebtahi, Wassim Allaham,[...]. Lancet Oncol 2017
334
8

Global patterns of hepatocellular carcinoma management from diagnosis to death: the BRIDGE Study.
Joong-Won Park, Minshan Chen, Massimo Colombo, Lewis R Roberts, Myron Schwartz, Pei-Jer Chen, Masatoshi Kudo, Philip Johnson, Samuel Wagner, Lucinda S Orsini,[...]. Liver Int 2015
449
7

Asia-Pacific clinical practice guidelines on the management of hepatocellular carcinoma: a 2017 update.
Masao Omata, Ann-Lii Cheng, Norihiro Kokudo, Masatoshi Kudo, Jeong Min Lee, Jidong Jia, Ryosuke Tateishi, Kwang-Hyub Han, Yoghesh K Chawla, Shuichiro Shiina,[...]. Hepatol Int 2017
781
7

A global view of hepatocellular carcinoma: trends, risk, prevention and management.
Ju Dong Yang, Pierre Hainaut, Gregory J Gores, Amina Amadou, Amelie Plymoth, Lewis R Roberts. Nat Rev Gastroenterol Hepatol 2019
871
7

Efficacy and safety of sorafenib in patients with advanced hepatocellular carcinoma: subanalyses of a phase III trial.
Jordi Bruix, Jean-Luc Raoul, Morris Sherman, Vincenzo Mazzaferro, Luigi Bolondi, Antonio Craxi, Peter R Galle, Armando Santoro, Michel Beaugrand, Angelo Sangiovanni,[...]. J Hepatol 2012
530
6

Assessment of liver function in patients with hepatocellular carcinoma: a new evidence-based approach-the ALBI grade.
Philip J Johnson, Sarah Berhane, Chiaki Kagebayashi, Shinji Satomura, Mabel Teng, Helen L Reeves, James O'Beirne, Richard Fox, Anna Skowronska, Daniel Palmer,[...]. J Clin Oncol 2015
943
6

Sorafenib or placebo plus TACE with doxorubicin-eluting beads for intermediate stage HCC: The SPACE trial.
Riccardo Lencioni, Josep M Llovet, Guohong Han, Won Young Tak, Jiamei Yang, Alfredo Guglielmi, Seung Woon Paik, Maria Reig, Do Young Kim, Gar-Yang Chau,[...]. J Hepatol 2016
349
6

Randomised, multicentre prospective trial of transarterial chemoembolisation (TACE) plus sorafenib as compared with TACE alone in patients with hepatocellular carcinoma: TACTICS trial.
Masatoshi Kudo, Kazuomi Ueshima, Masafumi Ikeda, Takuji Torimura, Nobukazu Tanabe, Hiroshi Aikata, Namiki Izumi, Takahiro Yamasaki, Shunsuke Nojiri, Keisuke Hino,[...]. Gut 2020
111
6

Predicting survival after liver transplantation in patients with hepatocellular carcinoma beyond the Milan criteria: a retrospective, exploratory analysis.
Vincenzo Mazzaferro, Josep M Llovet, Rosalba Miceli, Sherrie Bhoori, Marcello Schiavo, Luigi Mariani, Tiziana Camerini, Sasan Roayaie, Myron E Schwartz, Gian Luca Grazi,[...]. Lancet Oncol 2009
6

Management of hepatocellular carcinoma: an update.
Jordi Bruix, Morris Sherman. Hepatology 2011
6

Liver transplantation for the treatment of small hepatocellular carcinomas in patients with cirrhosis.
V Mazzaferro, E Regalia, R Doci, S Andreola, A Pulvirenti, F Bozzetti, F Montalto, M Ammatuna, A Morabito, L Gennari. N Engl J Med 1996
6

Brivanib versus sorafenib as first-line therapy in patients with unresectable, advanced hepatocellular carcinoma: results from the randomized phase III BRISK-FL study.
Philip J Johnson, Shukui Qin, Joong-Won Park, Ronnie T P Poon, Jean-Luc Raoul, Philip A Philip, Chih-Hung Hsu, Tsung-Hui Hu, Jeong Heo, Jianming Xu,[...]. J Clin Oncol 2013
507
5

Sunitinib versus sorafenib in advanced hepatocellular cancer: results of a randomized phase III trial.
Ann-Lii Cheng, Yoon-Koo Kang, Deng-Yn Lin, Joong-Won Park, Masatoshi Kudo, Shukui Qin, Hyun-Cheol Chung, Xiangqun Song, Jianming Xu, Guido Poggi,[...]. J Clin Oncol 2013
494
5

Hepatocellular carcinoma.
Hashem B El-Serag. N Engl J Med 2011
5

Lenvatinib as an Initial Treatment in Patients with Intermediate-Stage Hepatocellular Carcinoma Beyond Up-To-Seven Criteria and Child-Pugh A Liver Function: A Proof-Of-Concept Study.
Masatoshi Kudo, Kazuomi Ueshima, Stephan Chan, Tomohiro Minami, Hirokazu Chishina, Tomoko Aoki, Masahiro Takita, Satoru Hagiwara, Yasunori Minami, Hiroshi Ida,[...]. Cancers (Basel) 2019
77
6

The Burden of Primary Liver Cancer and Underlying Etiologies From 1990 to 2015 at the Global, Regional, and National Level: Results From the Global Burden of Disease Study 2015.
Tomi Akinyemiju, Semaw Abera, Muktar Ahmed, Noore Alam, Mulubirhan Assefa Alemayohu, Christine Allen, Rajaa Al-Raddadi, Nelson Alvis-Guzman, Yaw Amoako, Al Artaman,[...]. JAMA Oncol 2017
698
5

Phase III study of sorafenib after transarterial chemoembolisation in Japanese and Korean patients with unresectable hepatocellular carcinoma.
Masatoshi Kudo, Kazuho Imanaka, Nobuyuki Chida, Kohei Nakachi, Won-Young Tak, Tadatoshi Takayama, Jung-Hwan Yoon, Takeshi Hori, Hiromitsu Kumada, Norio Hayashi,[...]. Eur J Cancer 2011
378
5

Sorafenib with or without concurrent transarterial chemoembolization in patients with advanced hepatocellular carcinoma: The phase III STAH trial.
Joong-Won Park, Yoon Jun Kim, Do Young Kim, Si-Hyun Bae, Seung Woon Paik, Youn-Jae Lee, Hwi Young Kim, Han Chu Lee, Sang Young Han, Jae Youn Cheong,[...]. J Hepatol 2019
61
8

A clinical trial of CTLA-4 blockade with tremelimumab in patients with hepatocellular carcinoma and chronic hepatitis C.
Bruno Sangro, Carlos Gomez-Martin, Manuel de la Mata, Mercedes Iñarrairaegui, Elena Garralda, Pilar Barrera, Jose Ignacio Riezu-Boj, Esther Larrea, Carlos Alfaro, Pablo Sarobe,[...]. J Hepatol 2013
530
5

Phase Ib Study of Lenvatinib Plus Pembrolizumab in Patients With Unresectable Hepatocellular Carcinoma.
Richard S Finn, Masafumi Ikeda, Andrew X Zhu, Max W Sung, Ari D Baron, Masatoshi Kudo, Takuji Okusaka, Masahiro Kobayashi, Hiromitsu Kumada, Shuichi Kaneko,[...]. J Clin Oncol 2020
180
5

Y90 Radioembolization Significantly Prolongs Time to Progression Compared With Chemoembolization in Patients With Hepatocellular Carcinoma.
Riad Salem, Andrew C Gordon, Samdeep Mouli, Ryan Hickey, Joseph Kallini, Ahmed Gabr, Mary F Mulcahy, Talia Baker, Michael Abecassis, Frank H Miller,[...]. Gastroenterology 2016
255
5

Observational registry of sorafenib use in clinical practice across Child-Pugh subgroups: The GIDEON study.
Jorge A Marrero, Masatoshi Kudo, Alan P Venook, Sheng-Long Ye, Jean-Pierre Bronowicki, Xiao-Ping Chen, Lucy Dagher, Junji Furuse, Jean-Francois H Geschwind, Laura Ladrón de Guevara,[...]. J Hepatol 2016
164
5

Epidemiology and Management of Hepatocellular Carcinoma.
Laura Kulik, Hashem B El-Serag. Gastroenterology 2019
449
5

Tremelimumab in combination with ablation in patients with advanced hepatocellular carcinoma.
Austin G Duffy, Susanna V Ulahannan, Oxana Makorova-Rusher, Osama Rahma, Heiner Wedemeyer, Drew Pratt, Jeremy L Davis, Marybeth S Hughes, Theo Heller, Mei ElGindi,[...]. J Hepatol 2017
331
5

Hepatocellular carcinoma.
Josep M Llovet, Robin Kate Kelley, Augusto Villanueva, Amit G Singal, Eli Pikarsky, Sasan Roayaie, Riccardo Lencioni, Kazuhiko Koike, Jessica Zucman-Rossi, Richard S Finn. Nat Rev Dis Primers 2021
202
5

BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis.
Scott M Wilhelm, Christopher Carter, Liya Tang, Dean Wilkie, Angela McNabola, Hong Rong, Charles Chen, Xiaomei Zhang, Patrick Vincent, Mark McHugh,[...]. Cancer Res 2004
4

Immunological landscape and immunotherapy of hepatocellular carcinoma.
Jesús Prieto, Ignacio Melero, Bruno Sangro. Nat Rev Gastroenterol Hepatol 2015
288
4

Brivanib in patients with advanced hepatocellular carcinoma who were intolerant to sorafenib or for whom sorafenib failed: results from the randomized phase III BRISK-PS study.
Josep M Llovet, Thomas Decaens, Jean-Luc Raoul, Eveline Boucher, Masatoshi Kudo, Charissa Chang, Yoon-Koo Kang, Eric Assenat, Ho-Yeong Lim, Valerie Boige,[...]. J Clin Oncol 2013
426
4


Co-cited is the co-citation frequency, indicating how many articles cite the article together with the query article. Similarity is the co-citation as percentage of the times cited of the query article or the article in the search results, whichever is the lowest. These numbers are calculated for the last 100 citations when articles are cited more than 100 times.